Skip to main content

Ophthalmology and Therapy

Ausgabe 5/2024

Inhalt (22 Artikel)

Open Access COMMENTARY

A Patient-Centered Approach to Vernal Keratoconjunctivitis (VKC): A Podcast

Ann Cathrine Larsen, Marie Louise Roed Rasmussen

Open Access GUIDELINES

Diabetic Disease of the Eye in Canada: Consensus Statements from a Retina Specialist Working Group

Amer Omar, R. Geoff Williams, James Whelan, Jason Noble, Michael H. Brent, Michel Giunta, Sébastien Olivier, Mustapha Lhor

Open Access REVIEW

The Future of Checkpoint Inhibitors in Uveal Melanoma: A Narrative Review

Jinyu Wang, Zehua Li, Hongbo Yin

Open Access ORIGINAL RESEARCH

Automatic Detection of 30 Fundus Diseases Using Ultra-Widefield Fluorescein Angiography with Deep Experts Aggregation

Xiaoling Wang, He Li, Hongmei Zheng, Gongpeng Sun, Wenyu Wang, Zuohuizi Yi, A’min Xu, Lu He, Haiyan Wang, Wei Jia, Zhiqing Li, Chang Li, Mang Ye, Bo Du, Changzheng Chen

Open Access ORIGINAL RESEARCH

Detection of Retinal Microvascular Changes with Optical Coherence Tomography Angiography in Patients with Acute Leukemia Without Retinopathy

Miao Zhou, Kinji Hashimoto, Duo Wei, Yi Cai, Lvzhen Huang, Xuan Shi, Mingwei Zhao

Open Access ORIGINAL RESEARCH

A Novel Grading System for Diffuse Chorioretinal Atrophy in Pathologic Myopia

Yu-Ning Niu, Hai-Long He, Xuan-Yu Chen, Sai-Guang Ling, Zhou Dong, Ying Xiong, Yue Qi, Zi-Bing Jin

Open Access ORIGINAL RESEARCH

Clinical and Imaging Biomarkers Associated with Outer Retinal Atrophy Onset in Exudative Age-Related Macular Degeneration: A Real-Word Prospective Study

Alessandro Arrigo, Andrea Saladino, Emanuela Aragona, Costanza Barresi, Cecilia Mularoni, Francesco Bandello, Maurizio Battaglia Parodi

Open Access ORIGINAL RESEARCH

Short-Term Efficacy of Ophthalmic Cyclosporine: A 0.1% Cationic Emulsion in Dry Eye Patients Assessed Under Controlled Environment

Laura Valencia-Nieto, José Pinto-Fraga, Marta Blanco-Vázquez, Itziar Fernández, Alberto López-Miguel, Carmen García-Vázquez, María J. González-García, Amalia Enríquez-de-Salamanca, Margarita Calonge

Open Access ORIGINAL RESEARCH

Macular Neovascularization Secondary to Subclinical Angioid Streaks in Age-Related Macular Degeneration: Treatment Response to Anti-VEGF at 2-Year Follow-up

Riccardo Sacconi, Andrea Servillo, Federico Rissotto, Leonardo Bottazzi, Eliana Costanzo, Maria Sole Polito, Beatrice Tombolini, Mariacristina Parravano, Francesco Bandello, Giuseppe Querques

Open Access ORIGINAL RESEARCH

Diamond Bur Microblepharoexfoliation Combined with Intense Pulse Light and Meibomian Gland Expression for Evaporative Dry Eye: A Short-term Controlled Clinical Trial

Antonio Ballesteros-Sánchez, José-María Sánchez-González, Ramón Gutiérrez-Ortega, Beatriz Gargallo-Martínez

Open Access ORIGINAL RESEARCH

The Efficacy of Adalimumab in Children with Chronic Non-infectious Posterior Uveitis and Panuveitis: A Retrospective Cohort Study

Tianyu Tao, Shizhao Yang, Daquan He, Xuening Peng, Zhenyu Wang, Qi Jiang, Tianfu Wang, Wenru Su

Open Access ORIGINAL RESEARCH

Effect of Cyclotorsion Compensation in Small Incision Lenticule Extraction Surgery for the Correction of Myopic Astigmatism: A Systematic Review and Meta-Analysis

Xinwei Yang, Ying Liu, Kaimin Xiao, Qiuyi Song, Yunxi Xu, Jialing Li, Yuehua Zhou

Open Access ORIGINAL RESEARCH

Evaluation of a Digital Amsler Grid (PocDoc) for Macular Disease Screening: A Comparative Analysis with the Conventional Method

Joewee Boon, William Rojas-Carabali, Yusra Asad, Jonathan Tzien Yih Lim, Rajesh Rajagopalan, Rupesh Agrawal

Open Access ORIGINAL RESEARCH

Analytical and Functional Similarity of Aflibercept Biosimilar ABP 938 with Aflibercept Reference Product

Neungseon Seo, Xiaoyan Guan, Tian Wang, Hyo S. Helen Chung, Mats Wikström, Rupa Padaki, Kevin Kalenian, Scott Kuhns, Kelli Matthies, Jill Crouse-Zeineddini, Helen Y. Wong, Michael Ng, Ian N. Foltz, Shawn Cao, Jennifer Liu

Open Access ORIGINAL RESEARCH

Accuracy of Ten Intraocular Lens Formulas in Spherical Equivalent of Toric Intraocular Lens Power Calculation

Jingyi Shi, Zehui Zhu, Bin Hu, Shuyi Qian, Yalan Wang, Pingjun Chang, Yun-e Zhao

Open Access ORIGINAL RESEARCH

Clinical Characteristics and Treatment of Ophthalmic Sequelae of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis at a Tertiary Eyecare Centre in Hungary

Gábor Tóth, Andrea Lukács, Tanja Stachon, Frank Schirra, Gábor László Sándor, Zoltán Zsolt Nagy, Nóra Szentmáry

Open Access ORIGINAL RESEARCH

Real-World Safety Outcomes with Brolucizumab in Neovascular Age-Related Macular Degeneration: Findings from the IRIS® Registry

Marco A. Zarbin, Mathew W. MacCumber, Helene Karcher, Eser Adiguzel, Andrew Mayhook, Andrew LaPrise, Ver L. Bilano, Franklin Igwe, Michael S. Ip, Charles C. Wykoff

Open Access ORIGINAL RESEARCH

Efficacy, Safety and Immunogenicity of Sun’s Ranibizumab Biosimilar in Neovascular Age-Related Macular Degeneration: A Phase 3, Double-Blind Comparative Study

Asim K. Ghosh, Usha S. Nikumbh, Chaitanya K. Shukla, Rohit S. Laul, Abhishek Dixit, Santosh K. Mahapatra, Sameera Nayak, Urmil M. Shah, Sandeep Parwal, Narendran Venkatapathy, Natasha Radhakrishnan, Anup Kelgaonkar, Sandeep Saxena, Divyansh Mishra, Vivek Pravin Dave, Perwez Khan, Manojkumar R. Saswade, Malli S. Shantilal, Kim Ramasamy, Smitha Sreekanta, Mandodari Rajurkar, Maulik Doshi, Sapan Behera, Piyush Patel, Shilpi Dhawan, Lalit Lakhwani

Open Access ORIGINAL RESEARCH

Enhancing Diabetic Macular Edema Treatment Outcomes: Exploring the ESASO Classification and Structural OCT Biomarkers

Giacomo Panozzo, Maria V. Cicinelli, Giulia Dalla Mura, Diana Giannarelli, Maria Vadalà, Vincenza Bonfiglio, Giovanni Bellisario, Francesco Bandello, Edoardo Angelini, Pietro Airaghi, Teresio Avitabile, Andrea Beccastrini, Giorgia Benedetti, Federico Bertuzzi, Vincenza Maria Elena Bonfiglio, Francesco Boscia, Adriano Carnevali, Marianna Carosielli, Matteo Giuseppe Cereda, Cecilia Contardi, Michele Coppola, Ciro Costagliola, Riccardo Cristofolini, Pasquale Cucciniello, Rossella D’Aloisio, Maddalena Bernardo, Alessandro Filippis, Roberto Dell’Omo, Ilenia Paola, Matteo Dell’Acqua, Alessio Franco, Maria Oliva Grassi, Giulia Gregori, Elena Gusson, Rosangela Lattanzio, Paolo Lanzetta, Antonio Longo, Giorgio Marchini, Paola Marolo, Rodolfo Mastropasqua, Giuliana Mele Bertoldo, Giuseppina Monteleone, Elina Ortisi, Guglielmo Parisi, Salvatore Parrulli, Porzia Pucci, Marco Rocco Pastore, Michele Reibaldi, Stanislao Rizzo, Francesco Romano, Nicola Rosa, Valentina Sarao, Giuseppe Scarpa, Vincenzo Scorcia, Andrea Scupola, Giovanni Staurenghi, Valentina Sunseri Trapani, Daniele Tognetto, Giuseppe Trabucchi, Sabrina Vaccaro, Daniele Veritti, Alex Lucia Vinciguerra, Emma Clara Zanzottera

Open Access CASE REPORT

Rapid Vision Loss Due to Multifocal Glioma: A Diagnostic Challenge

Fletcher J. Ng, Wendy Wang, Laveniya Satgunaseelan, Nitin Verma

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.